Skip to content
TrialScanner

NCT03110575

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Phase 3TerminatedTNXPLead

Registry record

Lead sponsor
Tonix Pharmaceuticals, Inc.
Conditions
PTSD
Primary completion
Jul 27, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03110575 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03110575: 12-Week Open-Label Extension... | TrialScanner